{
    "clinical_study": {
        "@rank": "105938", 
        "arm_group": [
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive placebo prior to discharge and 6 weeks after discharge."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in\n      patients with stress hyperglycemia or mild diabetes following cardiac surgery.  Patients\n      will receive Sitagliptin or placebo.  Sitagliptin may be of particular use in this patient\n      population due to the effects on hepatic glucose production (a major feature of SH), safety\n      (lack of contra-indications for heart failure or renal failure and no hypoglycemia), and\n      tolerability.  The secondary objective of this study is to determine whether the management\n      of patients with persistent insulin requirements following cardiac surgery differs among\n      patients with stress hyperglycemia or mild diabetes."
        }, 
        "brief_title": "Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes Mellitus, Type 2", 
            "Hyperglycemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hyperglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia\n\n          -  AND:\n\n          -  Cardiac Surgery\n\n          -  Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off\n             pressors, off enteral feeding, extubated OR glucose >150 mg/dL at least twice in a 24\n             hour period (>4 hours apart) and otherwise not requiring basal insulin\n\n        Exclusion Criteria:\n\n          -  use of pressors, mechanical ventilation, or enteral or parenteral feeding within\n             previous 12 hours\n\n          -  glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the\n             previous 48 hours\n\n          -  left ventricular assist device\n\n          -  percutaneous or laparoscopic surgery\n\n          -  end stage renal disease\n\n          -  end stage liver disease\n\n          -  history of pancreatitis\n\n          -  type 1 diabetes\n\n          -  pregnancy\n\n          -  unable to give consent in english\n\n          -  no phone\n\n          -  prisoners\n\n          -  less than 18 years of age"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970462", 
            "org_study_id": "2013H0328"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin", 
                "description": "Sitagliptin prior to hospital discharge and 6 weeks following discharge.", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 27, 2013", 
        "location": {
            "contact": {
                "email": "kelly.rogers@osumc.edu", 
                "last_name": "Kelly E Rogers, MS", 
                "phone": "614-688-6885"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43203"
                }, 
                "name": "The Ohio State University Wexner Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery", 
        "other_outcome": [
            {
                "measure": "Self Monitored Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "2 and 6 weeks"
            }, 
            {
                "measure": "Adherence", 
                "safety_issue": "No", 
                "time_frame": "2 and 6 weeks"
            }, 
            {
                "measure": "Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "2 and 6 weeks"
            }
        ], 
        "overall_contact": {
            "email": "kelly.rogers@osumc.edu", 
            "last_name": "Kelly E Rogers, MS", 
            "phone": "6146886885"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University", 
            "last_name": "Kathleen M Dungan, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Difference in Fasting Glucose", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970462"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Ohio State University", 
            "investigator_full_name": "Kathleen Dungan", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Ohio State University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kathleen Dungan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}